From: Current and emerging therapies for primary central nervous system lymphoma
Targeted therapy | Adverse events | ||
---|---|---|---|
Events | Any grade | Grade≥3 | |
neutropenia | 25%(5/20)~40%(6/15), | 3.8%(2/52)~ 83%(15/18) | |
anemia | 70%(14/20)~100%(15/15) | 5%(1/20)~20%(3/15) | |
thrombocytopenia | 70%(14/20) | 10%(2/20)~72%(13/18) | |
febrile neutropenia | 5%(1/25) | 1.9%(1/52)~61%(11/18) | |
increased creatinine | 27%(4/15)~30%(6/20) | 27%(4/15) | |
increased ALT | 3.8%(2/52)~80%(12/15) | 7%(1/15)~10%(2/20) | |
diarrhea | 3.8%(2/52)~25%(5/20) | 7%(1/15)~11%(2/18) | |
prolonged APTT | 20%(3/15)~30%(6/20) | 10%(2/20) | |
infection | 9.6%(5/52)~27%(4/15) | 5.8%(3/52)~78%(14/18) | |
atrial fibrillation | 3.8%(2/52) | 1.9%(1/52) | |
neutropenia | Â | 21.4%(3/14)~40%(20/50) | |
thrombocytopenia | Â | 10%(5/50) | |
anemia | Â | 4%(2/50) | |
infection | Â | 8%(4/50)~21.4%(3/14) | |
Pomalidomide [15] | neutropenia | 100%(25/25) | 20%(5/25) |
thrombocytopenia | 44%(11/25) | 8%(2/25) | |
anemia | 80%(20/25) | 8%(2/25) | |
thromboembolism | 8%(2/25) | Â | |
infection | 44%(11/25) | 16%(4/25) | |
fatigue | 40%(10/25) | 8%(2/25) | |
dyspnea, hypoxia and/or respiratory failure | 16%(4/25) | 16%(4/25) | |
nivolumab [77] | pruritus | 20%(1/5) | Â |
fatigue | 20%(1/5) | Â | |
renal insufficiency | 20%(1/5) | 20%(1/5) | |
NGR-hTNF [78] | neutropenia | 89%(25/28) | 85%(24/28) |
thrombocytopenia | 85%(24/28) | 61%(17/28) | |
anemia | 85%(24/28) | 21%(6/28) | |
febrile neutropenia | 14%(4/28) | 14%(4/28) | |
infection | 14%(4/28) | 14%(4/28) | |
deep vein thrombosis | 7%(2/28) | 7%(2/28) | |
infusion reaction | 32%(9/28) | Â | |
hepatotoxicity | 50%(14/28) | 18%(5/28) |